Association between treatment effect on C‐peptide preservation and HbA1c in meta‐analysis of glutamic acid decarboxylase (GAD)‐alum immunotherapy in recent‐onset type 1 diabetes
Open Access
- 26 May 2022
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 24 (8) , 1647-1655
Abstract
No abstract availableKeywords
Funding Information
- Barndiabetesfonden
- Diabetesfonden
- Western Michigan University
This publication has 12 references indexed in Scilit:
- Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet Diabetes & Endocrinology, 2021
- Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetesDiabetologia, 2020
- A quantitative measure of treatment response in recent‐onset type 1 diabetesEndocrinology, Diabetes & Metabolism, 2020
- Teplizumab Preserves C-Peptide in Recent-Onset Type 1 DiabetesDiabetes, 2013
- GAD65 Antigen Therapy in Recently Diagnosed Type 1 Diabetes MellitusNew England Journal of Medicine, 2012
- Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trialThe Lancet, 2011
- GAD Treatment and Insulin Secretion in Recent-Onset Type 1 DiabetesNew England Journal of Medicine, 2008
- C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve β-Cell FunctionDiabetes, 2004
- β-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control and Complications TrialDiabetes Care, 2003
- Effect of Intensive Therapy on Residual β-Cell Function in Patients with Type 1 Diabetes in the Diabetes Control and Complications TrialAnnals of Internal Medicine, 1998